PROF earnings analysis
What we found in PROF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Profound Medical reported Q1 2026 revenue of $5.3 million, a 104% increase from $2.6 million in Q1 2025, marking significant growth as net loss improved to $7.0 million from $10.7 million year-over-year. The company achieved a gross margin of 72%, reflecting a slight increase from prior periods, with decreased operating expenses contributing to the narrower loss.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Up 104% Year-Over-Year
- Revenue grew to $5.3 million from $2.6 million in Q1 2025.
- Narrowed Net Loss
- Net loss improved to $7.0 million from $10.7 million in the prior year.
- Operating Expenses Reduced
- Total operating expenses decreased by 9% to $11.9 million from $13.0 million in Q1 2025.
- High Gross Margin Maintained
- Gross margin remains strong at 72%, slightly up from 71% in the previous year.
- Increased Product Adoption
- Capital equipment sales significantly contributed to revenue growth.
- Decreased SG&A Expenses
- SG&A expenses dropped by 20% to $6.6 million from $8.2 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Expenses Persist
- Operating expenses remain high at $11.9 million despite reductions.
- Clinical Trials Dependency
- The company's growth is closely tied to the success of ongoing clinical trials.
- Market Acceptance Risks
- Continued revenue growth depends on broader market acceptance of TULSA-PRO and Sonalleve.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.19
- Gross margin
- 72%
- Segment
- TULSA-PRO
- Segment
- Sonalleve
What they said about what is next.
Management anticipates full-year 2026 revenue of approximately $25 million, marking a targeted 56% growth from the previous year.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PROF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever